Virios Therapeutics Inc.

06/02/2021 | Press release | Archived content

Virios Therapeutics Presents Phase 2a Fibromyalgia Trial Data on Efficacy Analyses of Key Secondary Endpoints at the EULAR European Congress of Rheumatology